Laser assisted immunotherapy (LIT) for chemotherapy-resistant neoplasms: recent case reports

Robert E. Nordquist; Cody Bahavar; Feifan Zhou; Tomas Hode; Wei R. Chen; Xiaosong Li; Mark F. Naylor

doi:10.1117/12.2041646

27 February 2014 Laser assisted immunotherapy (LIT) for chemotherapy-resistant neoplasms: recent case reports

Robert E. Nordquist, Cody Bahavar, Feifan Zhou, Tomas Hode, Wei R. Chen, Xiaosong Li, Mark F. Naylor

Author Affiliations +

Proceedings Volume 8944, Biophotonics and Immune Responses IX; 894406 (2014) https://doi.org/10.1117/12.2041646
Event: SPIE BiOS, 2014, San Francisco, California, United States

Abstract

T-cell stimulators such as anti-CTLA-4 antibodies enhance immunologic responses to chemotherapy-resistant solid tumors, such as melanoma, advanced breast cancer, ovarian cancer and pancreatic cancer. The efficacy of these new immunotherapy agents can in theory be enhanced substantially by therapies that stimulate new immunologic (T-cell) responses against the tumor. Laser immunotherapy (LIT) with imiquimod and InCVAX are techniques that produce useful responses in patients with advanced melanoma, the prototypical chemotherapy resistant solid tumor. The mechanism of action of these therapies is thought to be immunological, including the development of new T-cell responses. We have therefore been combining LIT using imiquimod and InCVAX treatment with the new T-cell stimulators (ipilimumab) in cases of stage IV melanoma. While still anecdotal, the use of novel combinations of immunologic therapies should provide much improved responses for chemotherapy-resistant solid tumors (such as melanoma) than was previously possible. Newer T-cell stimulating drugs such as the anti-PD-1 antibodies and anti-PD-L1 antibodies will make this general approach to treating chemoresistant advanced tumors even more effective in the future.

Citation Download Citation

Robert E. Nordquist, Cody Bahavar, Feifan Zhou, Tomas Hode, Wei R. Chen, Xiaosong Li, and Mark F. Naylor "Laser assisted immunotherapy (LIT) for chemotherapy-resistant neoplasms: recent case reports", Proc. SPIE 8944, Biophotonics and Immune Responses IX, 894406 (27 February 2014); https://doi.org/10.1117/12.2041646

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

;

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE